Member Info for Uncanny

Gilders, I’m really sorry to hear that news mate and I’m sure all on this board know somebody that has passed or been affected by the big C. It really is one of the biggest 20 century killers!

Granger do you really think with Mark being underwater with his previous investment before he started his tenure, then investing £150,000 3 months ago with 30 years science and commercial bio experience, with a PhD really is not savvy enough to realise what he’s investing in?

I said before, let’s just wait and see how this pans out before everybody jumps to premature conclusions.

GLA

I think let’s see how things pan out before casting judgement prematurely . GLA

I forget to say that l agree Nick, if 201 comes off then we will be 5-10p per share as that would be pricing about 30% of the total deal in on the current number of shares in issue.

Happy weekend all.

Lol, have a good weekend!

Nicce flurry of buying now as people I presume see value here at this level.

Maybe Nick ; ) and need to RNS for each round 1% reached up (or down) on my 5.84% I believe?

Are you?

Oh dear, handbags at dawn here LOL - relax everyone it's Friday and you are either in or out, long or short, looking to buy in lower or sell out higher.

Each to their own and let's all be civil as life is far too short.

"Nick’ analysis is absolutely spot on as per usual." Is that because you are the same people? LOL

Hoosier, I liked De Courcey don't get me wrong but I'd rather have an experienced scientist with 6% skin in the game with a commercial background leading the charge as CEO.

G14, maybe you should read the full data set result summary again as that is not what I read:

The headline results released in the Company announcement on 28 September 2020 highlighted the response rate of 54.5%, where response was confirmed by a lack of disease progression by PCWG2 (Prostate Cancer Working Group 2) criteria.

· The PSA data, a recognised surrogate of disease progression, shows ....treatment period maintained the decrease throughout the trial. An analysis of the doubling time of patients shows a statistically significant (p

· The tumour response data demonstrates that patients did not have an increase in metastatic lesions during the treatment period, and that metastatic lesions already present did not grow at all suggesting a positive influence of VAL201 on the disease.

Safety and Tolerability - The further breakdown of the safety data confirms the well tolerated nature of the drug.

Why would VAL be offered $2.2mn upfront plus fees, $67mn total deal and $33mn for each new indication if it was non-starter?

Indeed UXM, the global pet cancer market is worth 1/2 billion dollar and is expected to grow by 9.7% every year from 2025 to 2034, so a massive market and a very much welcomed new business area for VAL to adopt aligned next to its human women's health / oncology offerings IMHO.

Absolute rubbish Grainger - GM got kicked out at a shareholder vote and 201 results were good with initial CT 1 with a 56% positive correlation in testing and still in play under LOI, 301 relates to 201 as the same science and simply frozen to concentrate on assets closer to commercialising and 401 is with some pre-eminent scientists at Ambrose under evaluation that know a lot more than you and I, so they obviously see value there which is a circa 16mn deal.

At appointment in Cathy who I think is superb plus for those demanding it, headcount is reduced and a cost saving of £200K pa - whats not to like!

Don't think 3 x PhD scientists at VAL would have pushed it through clinical trials if that was the case, plus didn't it have exceptional data at over 56%?

Thanks Nom and yes, you are quite right so it would be potentially worth 11p alone!

Maybe I get my morning coffee first before I post ! LOL

Is the sale of 201 shares cryptic? LOL

I think the SP is currently priced in to failure so hopefully minimal downside from here.

Forgetting all the IP, VAL has 4,000 vials worth £10K per vial as per recent RNS - "Inaphaea will be entitled to an upfront fee of £10,000 per PDC cell line", either from this or future deals

Thats £4,000,000, plus the company also raised £2,437,500 (plus the same again when the warrants are exercised) , so even assuming 3 of 12 months has been used, that still at the current shares in issue of 375mn equates is 1.7p per share.

Then add in any or all of what you would value 201. 401, Stingray, CLX, the lab at?

Or even better a commercial deal for any of the above and the new SPV and future evaluations TBC!?

Well it certainly isn't 0.6p per share IMHO!

DYOR, NAI

Hoosier - where exactly do you think they will do a deal for CLX.... someone just knocks on the door in Nuneaton and writes a cheque?

If you read LinkedIn you will see VAL CEO and CLX Co-Founder are both attending Immune Oncology 360 Conference to promote CLX.

Great!

Mark also says at the end of the piece from Mark - "thanks for your hospitality!

If 201 come in then a complete game changer as 2.2 million upfront and a 67 million total potential deal plus 33 million for each new indication so the SP should be many multiples of whee we are now ands also the warrants are also triggered too so no more fund raises for quite some time and plenty of cash in the bank!

GLA and yes the next couple of months could be very interesting!

Sadly an external CEO would have demanded twice the salary that ME is getting plus would they also subscribe £120k of their own personal monies in the recent fund raise?

We are only just over mid March since ME’s tenure and there has been lots put in to place already, a lot behind closed doors and much more to come l am sure.

GLA